Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Formulations of bendamustine

a technology of bendamustine and edema, which is applied in the field of bendamustine forms, can solve the problems of inability to tolerate high-dose edema, so as to avoid side effects

Inactive Publication Date: 2014-04-03
EAGLE PHARMACEUTICALS INC
View PDF4 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The methods in this patent take advantage of a fact that the concentration of bendamustine HCl is below the room temperature solubility limit of the vehicle into which it is placed. This helps to prevent the bendamustine from precipitating during administration to the patient. This avoids the side effects that would otherwise occur during small volume administration of therapeutic doses of the drug. In addition, patients or subjects with bendamustine-responsive conditions can be treated using smaller parenteral volumes, which are well below the standard 500 ml administration volume.

Problems solved by technology

; administration must be completed within this period due to limited chemical stability in aqueous solutions.
Higher infusion volume and longer infusion times, however, are associated with many drawbacks.
From patient comfort and nursing administration points of view, higher infusion volumes and long infusion times are undesirable.
Higher infusion volumes may be associated with higher likelihood of weight gain and edema.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0040]The solubility of bendamustine HCl, obtained from two different sources, in 0.9% saline and 0.9% saline containing from different amounts of a non-aqueous solubilizer comprising a mixture of polyethylene glycol 400 and propylene glycol (in the volume proportion of 90:10) with and without 5 mg / ml monothioglycerol was determined at both room temperature (22-23° C.) and at refrigerated temperature (5° C.). Essentially, an excess of bendamustine HCl was added to solvents comprising of various volume percent of the non-aqueous solubilizer in 0.9% saline, and allowed to equilibrate with shaking for 30 minutes at room temperature, or for 24 hours at refrigerated temperature. At the end of the equilibration step, the suspensions were filtered through a 0.2 micron filter to remove undissolved bendamustine, and the filtrate solutions analyzed for bendamustine HCl content using a HPLC assay; quantification was performed against a bendamustine HCl reference standard. The solubility data a...

example 2

[0041]Bendamustine-containing compositions are prepared by adding 5 mg / ml of thioglycerol to a mixture containing 90% polyethylene glycol 400 and 10% propylene glycol. As indicated in the Table 2 below, NaOH may be added to the PEG in an amount sufficient to get apparent pH of greater than or equal to 6.5 as measured using the pH method outlined in the USP monograph for polyethylene glycol (PEG). Bendamustine (BDM) is then added to the sample to a concentration of 10 mg / ml.

TABLE 2FormulationBDM - 10 mg / mLThioglycerol - 5 mg / mLPEG 400:PG (90:10)qs to 1 mLBDM - 10 mg / mLThioglycerol - 5 mg / mLPEG 400:PG (90:10)qs to 1 mL(PEG 400 Treated withNaOH)

[0042]The compositions are then admixed with normal saline based on the total dose of bendamustine HCl, which in turn is based on the patient body surface area (BSA) and the dosing regimen (100 mg / m2 for CLL and 120 mg / m2 for NLL; although dose modifications of 90, 60, 50, and 25 mg / m2 are possible, only the highest two dosing regimens are consi...

example 3

[0044]The procedures of Example 2 are repeated except that the dose appropriate volume of the 10 mg / ml bendamustine solution is diluted into 250 ml of normal saline. The final concentration of bendamustine in the 250 ml volume container ranges from about 0.05 mg / ml to about 1.3 mg / ml.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
volumeaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of application Ser. No. 13 / 838,090, filed Mar. 15, 2013, which claims the benefit of priority from U.S. Provisional Patent Application Ser. Nos. 61 / 613,173, filed Mar. 20, 2012, and 61 / 669,889, filed Jul. 10, 2012, the disclosures of each of which are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]Bendamustine is used in the treatment of a number of cancers including leukemias, Hodgkin's disease and multiple myelomas. Bendamustine (present as the HCl salt) is the active ingredient of the commercial product Treanda™, a lyophilized powder for reconstitution. Current labeling requirements call for the reconstituted product to be immediately (within 30 minutes) diluted into 500 mL of parenterally acceptable diluents such as 0.9% saline (normal saline) or 2.5% dextrose / 0.45% saline and administered as part of an intravenous infusion delivering 100 mg / m2 over 30 minutes or 120 mg / m2 over 60 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4184
CPCA61K31/4184A61K9/0019A61K47/10A61P35/00A61P35/02A61K47/20A61K47/02A61K47/22
Inventor SUNDARAM, SRIKANTH
Owner EAGLE PHARMACEUTICALS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com